On Friday, MEDNAX Inc(NYSE:MD)’s shares inclined 3.17% to $84.64.
MEDNAX, Inc. (MD), the national medical group specializing in neonatal and other pediatric services, anesthesia, maternal-fetal, pediatric cardiology and other physician and administration services, recently stated earnings of $0.90 per diluted share for the three months ended June 30, 2015, an enhance of 14% over the preceding-year period. On an adjusted, non-GAAP basis, MEDNAX stated EPS of $1.02, an enhance of 16% over the preceding-year period.
For the 2015 second quarter contrast to the preceding year period, MEDNAX stated:
- Revenue growth of 13.6 percent to $677 million;
- Operating income growth of 8.7 percent to $141 million;
- EBITDA growth of 11.8 percent to $157 million;
- EPS growth of 13.9 percent to $0.90 and Adjusted EPS growth of 15.9 percent to $1.02.
MEDNAX, Inc., together with its auxiliaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain administration services.
Pacira Pharmaceuticals Inc(NASDAQ:PCRX)’s shares gained 7.48% to $66.42.
Pacira Pharmaceuticals, Inc. (PCRX) offered updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and declared merged financial results for the second quarter ended June 30, 2015.
Recent Developments
- Path Forward for EXPAREL Use in Nerve Block: In May, Pacira declared the completion of the end-of-review process with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products (DAAAP) of the Center for Drug Evaluation and Research regarding the supplemental New Drug Application (sNDA) for the use of EXPAREL for administration as a nerve block to provide postsurgical analgesia. Based upon the FDA guidance that the predictable use of EXPAREL will be for a broad spectrum of nerve blocks and not limited to the narrow indication of a single nerve block, Pacira plans to conduct additional Phase 3 studies for upper and lower extremity nerve blocks, and anticipates to initiate these studies by the end of 2015.
- DepoFoam® Spray Manufacturing Process Update: Pacira requested a Type C meeting with the FDA in March to talk about the DepoFoam spray manufacturing process for EXPAREL. In May, Pacira declared feedback that the projected approach to demonstrate comparability and to provide adequate data in support of the spray process appears acceptable.Based on this feedback, Pacira intends to pursue the manufacturing of DepoFoam-based products using the spray process.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The companys lead product comprise, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.
At the end of Friday’s trade, Oculus Innovative Sciences, Inc. (NASDAQ:OCLS)‘s shares dipped -19.21% to $1.43.
Oculus Innovative Sciences, Inc. (OCLS) declared financial results for the first quarter of fiscal year 2016, which ended on June 30, 2015. Total revenue was $3.7 million for the first quarter, up 8%, when contrast to $3.4 million for the same period in fiscal year 2015. Product revenues were up 37% from the same period last year, led by enhances in the United States and Mexico.
Results for the Three Months Ended June 30, 2015
Product revenues in the United States were $787,000 for the three months ended June 30, 2015, as contrast to $355,000 in the quarter ended June 30, 2014. Product revenues were up $432,000, or 122%, from the same period last year due to higher sales in dermatology and acute care products. In the quarter ending December 2014, Oculus deployed a direct sales force focused on dermatology, which has launched four new dermatology products for the treatment of atopic dermatitis, scars and surgical procedures.
Product revenue in Mexico of $1.6 million for the three months ended June 30, 2015, raised by $465,000, or 43%, when contrast to the same period in the preceding year. On a local currency basis, product revenue growth was 68% contrast to the same period last year. This growth in sales is primarily due to the much larger sales force and distribution network of our new partner, Laboratorios Sanfer, which attained our former Latin American partner, More Pharma, in January 2015.
Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue and skin care, and animal healthcare markets in the United States, Mexico, Europe, and internationally.
KBR, Inc.(NYSE:KBR), ended its Friday’s trading session with -1.02% loss, and closed at $17.48.
KBR, Inc. (KBR) declared that it has received an award associated with the Fort Hills Oil Sands Mining Project. KBR won a reimbursable contract to provide construction services at the facility located 90 kilometers north of Fort McMurray, Alberta.
KBR’s scope comprises onsite construction administration and direct hire field construction services at the Fort Hills Secondary Extraction facility. This scope, which was awarded by SK E&C partner Sunlake, follows KBR’s contract to perform a detailed constructability study for the project.
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services. The Technology & Consulting segment offers various services and solutions, counting licensing, engineering and design, proprietary equipment, plant automation, catalysts, and related consulting services to hydrocarbons, chemicals, and fertilizer markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
